Debora A. Grahl a, b , Jonas Axelsson a , Louise Nordfors a , Olof Heimbürger a , Peter Bárány a , Abdul Rashid Qureshi a , Sawako Kato a , Makoto Watanabe a , Mohamed Suliman a , Miguel C. Riella b , Bengt Lindholm a , Peter Stenvinkel a , Roberto Pecoits-Filho a, b
01 March 2007
Genetic variations in the NADPH/MPO system in chronic kidney disease (CKD) patients might lead to altered activity of these enzymes, and thus to altered risk for oxidative stress (OS) and cardiovascular disease (CVD). We evaluated the impact of 242C/T CYBA and –463G/A MPO polymorphisms on OS and CVD mortality in stage 5 CKD patients starting dialysis. Two hundred and fifty-seven patients were genotyped using Pyrosequencing. Plasmalogen [dimethylacetal (DMA) 16/C16:0] was used as OS marker. CVD was assessed from patient history and clinical symptoms. Prevalence of CVD was higher (35%) in GG patients ( MPO) compared to AG (26%) and AA (0%) patients (p < 0.01). Patients with CC genotype ( CYBA) had lower levels of DMA 16/C16:0 (ratio 0.071 ± 0.003) compared to TT patients (0.089 ± 0.006; p < 0.05). These patients also had increased CVD mortality compared to CT and TT patients (χ<sup>2</sup> 2.19; p < 0.05). We conclude that genetic variations in the NADPH/MPO system are associated with OS, presence of CVD and CVD-related mortality in CKD patients.